About Dr. Paul G. Harch
Dr. Paul G. Harch, MD, is a distinguished clinician in emergency medicine and hyperbaric medicine with extensive experience in treating various neurological conditions. He was the former director of the University Medical Center Hyperbaric Medicine Department and LSU Hyperbaric Medicine Fellowship and is currently a Clinical Professor of Medicine in
Dr. Paul G. Harch's Credentials
Education & Certificates
Here are the degrees that Dr. Paul G. Harch MD has obtained
- Doctor of Medicine - John Hopkins University School of Medicine, 1976-1980
- Bachelor of Science, Biology, Magna cum laude, Phi Beta Kappa - The University of California, Irvine
Post-Graduate Training
- 13th Annual National Oceanographic and Atmospheric Administration Physician Diving Accident Medical Management Course, NOAA facility, Key Biscayne, FL, September 1987
- Radiology resident, Louisiana State University School of Medicine, Charity Hospital, New Orleans, July 1986 - July 1987
- Orientation course in hyperbaric oxygen therapy, Long Beach Medical Center, Long Beach, CA, June 1986
- Two years general surgery training at the University of Colorado Health Sciences Center, Denver, Colorado, with six months leave for auto-ped accident, June of 1980-December of 1982
Specialties
- Hyperbaric medicine
- Traumatic Brain Injury
- HBOT and neurological disorders
- Emergency medicine
- HBOT and SPECT brain imaging
Typical Program Length
Dr. Paul G. Harch MD provides a la carte services at Harch HBOT
Years of Experience
Languages Spoken
- English
Gender
NPI Number
Where Dr. Paul G. Harch practices
Books authored by Dr. Paul G. Harch
The Oxygen Revolution, Third Edition: Hyperbaric Oxygen Therapy (HBOT): The Definitive Treatment of Traumatic Brain Injury (TBI) & Other Disorders
Cutting-edge research on hyperbaric oxygen therapy (HBOT) as a gene therapy to treat traumatic brain injuries, degenerative neurological diseases, and other disorders Hyperbaric oxygen therapy (HBOT) is based on a simple idea—that oxygen can be used therapeutically for a wide range of conditions where tissues have been damaged by oxygen deprivation. Inspiring and informative, The Oxygen Revolution, Third Edition is the comprehensive, definitive guide to the miracle of hyperbaric oxygen therapy. HBOT directly affects the body at the genetic level, affecting over 8,000 individual genes—those responsible for healing, growth, and anti-inflammation. Dr. Paul G. Harch’s research and clinical practice has shown that this noninvasive and painless treatment can help those suffering from brain injury or such diseases as: • Stroke • Autism and other learning disabilities • Cerebral palsy and other birth injuries • Alzheimer’s, Parkinson’s, multiple sclerosis, and other degenerative neurological diseases • Emergency situations requiring resuscitation, such as cardiac arrest, carbon monoxide poisoning, or near drowning
Podcasts with Dr. Paul G. Harch
The Miraculous Benefits of Hyperbaric Oxygen Therapy – Episode 116: Dr. Paul Harch
Ann Louise Gittleman, your host for the First Lady of Nutrition podcast, recently completed 40 hyperbaric oxygen treatments at the Harch HBOT in New Orleans. She couldn’t wait to share the phenomenal health benefits of an often-ignored therapy like HBOT. And so, she is thrilled to welcome Paul G. Harch, M.D., a world-renowned expert in hyperbaric oxygen treatment! As the author of the recently published book, “The Oxygen Revolution,” Dr. Harch discusses the fascinating history and profound efficacy of HBOT to treat more than 100 different conditions, including stroke, dementia, autism, traumatic brain injury, and cancer. As Dr. Harch mentions in the podcast, HBOT is really gene therapy. He continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world, and patients from over 50 countries have come to Dr. Harch to receive hyperbaric oxygen therapy. In March 2020 he proposed the application of HBOT to COVID-19 pneumonia based on the successful use of hyperbaric treatment for dying Spanish Flu patients in 1918 and has now successfully treated patients with COVID-19 Long-Haulers Syndrome.
